论文部分内容阅读
目的:探讨依达拉奉与奥扎格雷钠联用治疗急性脑梗死患者的疗效及其对血清炎性因子水平和自由基的影响。方法:选取2013年4月—2016年12月间收治的急性脑梗死患者89例,采用随机分组法将其分为对照组45例和观察组44例;对照组患者给予奥扎格雷钠常规治疗,观察组患者在对照组基础上加用依达拉奉治疗,比较两组患者治疗前后血清白介素-10(IL-10)、肿瘤坏死因子(TNF-α)、超敏C反应蛋白(Hs-CRP)等炎症指标及丙二醛(MDA)、超氧化物歧化酶(SOD)等氧化指标的改善情况;以及两组患者神经功能NIHSS评分值的改善情况及临床疗效。结果:治疗后观察组患者TNF-α、Hs-CRP下降,IL-10升高,优于对照组(P<0.05);MDA和NIHSS评分值下降,SOD则升高优于对照组(P<0.05);观察组患者的总有效率为93.18%高于对照组为75.56%(P<0.05)。结论:采用依达拉奉与奥扎格雷钠联用治疗急性脑梗死患者,可有效改善脑梗后炎症反应,促进神经功能的恢复,临床疗效优于单用奥扎格雷钠的治疗。
Objective: To investigate the therapeutic effect of edaravone and ozagrel sodium on patients with acute cerebral infarction and its effect on the levels of serum inflammatory cytokines and free radicals. Methods: A total of 89 acute cerebral infarction patients admitted from April 2013 to December 2016 were randomly divided into control group (n = 45) and observation group (n = 44). Patients in the control group were treated with ozagrel sodium . The patients in the observation group were treated with edaravone on the basis of the control group. The levels of serum interleukin-10, tumor necrosis factor-α (TNF-α) and hypersensitive C-reactive protein (Hs- CRP) and other indicators of inflammation and malondialdehyde (MDA), superoxide dismutase (SOD) and other indicators of the improvement; and two groups of patients with neurological NIHSS score improvement and clinical efficacy. Results: After treatment, the levels of TNF-α, Hs-CRP and IL-10 in the observation group were significantly higher than those in the control group (P <0.05); MDA and NIHSS scores decreased and SOD increased more than the control group (P < 0.05). The total effective rate in the observation group was 93.18% higher than that in the control group (75.56%, P <0.05). Conclusion: The combination of edaravone and ozagrel sodium in patients with acute cerebral infarction can effectively improve the inflammatory response after cerebral infarction and promote the recovery of neurological function. The clinical efficacy is better than that of ozagrel sodium alone.